Ardelyx (NASDAQ:ARDX) Research Coverage Started at TD Cowen

TD Cowen began coverage on shares of Ardelyx (NASDAQ:ARDX) in a report released on Wednesday,Zacks reports. The brokerage issued a strong-buy rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on ARDX. Citigroup reduced their price target on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, August 10th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Ardelyx in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ardelyx in a research note on Friday, September 25th. Piper Sandler decreased their target price on shares of Ardelyx from $16.00 to $15.00 and set an “overweight” rating on the stock in a research report on Monday, August 17th. Finally, Zacks Research upgraded Ardelyx from a “strong sell” rating to a “hold” rating in a report on Friday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $13.90.

Ardelyx Stock Down 3.7%

Shares of ARDX opened at $2.88 on Wednesday. The company has a 50-day moving average price of $3.35 and a two-hundred day moving average price of $5.23. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.69. Ardelyx has a 12 month low of $2.84 and a 12 month high of $8.40. The stock has a market cap of $717.67 million, a price-to-earnings ratio of -13.09 and a beta of 0.79.

Ardelyx (NASDAQ:ARDX) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Ardelyx had a negative return on equity of 36.00% and a negative net margin of 12.35%. The company had revenue of $120.88 million for the quarter, compared to the consensus estimate of $121.03 million. During the same period in the previous year, the firm posted ($0.08) EPS. The business’s quarterly revenue was up 34.3% on a year-over-year basis. Equities analysts predict that Ardelyx will post -0.18 EPS for the current fiscal year.

Insider Activity

In other news, insider Eric Foster sold 8,562 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $33,049.32. Following the completion of the transaction, the insider owned 409,410 shares of the company’s stock, valued at $1,580,322.60. The trade was a 2.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider James Brady sold 15,136 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $58,424.96. Following the completion of the sale, the insider owned 245,930 shares in the company, valued at $949,289.80. The trade was a 5.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 126,059 shares of company stock valued at $486,588. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Ardelyx

A number of large investors have recently made changes to their positions in ARDX. BlackRock Inc. acquired a new position in Ardelyx during the 2nd quarter valued at about $119,874,000. Jupiter Topco LLC bought a new position in Ardelyx during the second quarter worth about $27,043,000. AIGH Capital Management LLC bought a new stake in shares of Ardelyx in the 2nd quarter worth approximately $16,320,000. Bank of America Corp DE bought a new stake in shares of Ardelyx during the 2nd quarter valued at $11,034,000. Finally, Rubric Capital Management LP bought a new position in shares of Ardelyx in the 1st quarter worth approximately $11,147,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

Ardelyx News Summary

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: TD Cowen initiated coverage with a “Strong Buy” rating and reaffirmed its “Buy” view. HC Wainwright also raised its Q4 2026 and FY2026 earnings estimates while maintaining a $13 price target. TD Cowen coverage
• Neutral Sentiment: Ardelyx reported break-even quarterly EPS, beating the consensus estimate of a $0.02 loss, while revenue of $127.66 million narrowly missed forecasts. Revenue rose 21% year over year. Quarterly results
• Negative Sentiment: HC Wainwright cut its EPS estimates for FY2027 through FY2030, including a reduction for FY2029 from $1.56 to $1.18. The cuts temper the bullish implications of its higher near-term forecasts, despite its continued “Buy” rating and $13 target. Analyst estimates
• Negative Sentiment: Law firms are publicizing a filed securities class action covering investors who bought shares from January 13, 2025, through August 6, 2026; the lead-plaintiff deadline is November 16. The complaint alleges Ardelyx misrepresented payer access and reimbursement barriers affecting IBSRELA and XPHOZAH, and its sales outlook. The allegations are unproven, but the litigation adds uncertainty. Class action notice and allegations

About Ardelyx

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.